Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis evaluated onset of action and maintenance of respons...

Full description

Saved in:
Bibliographic Details
Main Authors: Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Clinical trials
deucravacitinib
maintenance of response
onset of action
phase 3
psoriasis
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2371045
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2024.2371045

Similar Items